JP2002502884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002502884A5 JP2002502884A5 JP2000531189A JP2000531189A JP2002502884A5 JP 2002502884 A5 JP2002502884 A5 JP 2002502884A5 JP 2000531189 A JP2000531189 A JP 2000531189A JP 2000531189 A JP2000531189 A JP 2000531189A JP 2002502884 A5 JP2002502884 A5 JP 2002502884A5
- Authority
- JP
- Japan
- Prior art keywords
- interleukin
- herpes simplex
- suspension
- simplex virus
- alum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 19
- 102000013462 Interleukin-12 Human genes 0.000 description 12
- 108010065805 Interleukin-12 Proteins 0.000 description 12
- 229940117681 interleukin-12 Drugs 0.000 description 12
- 241000700584 Simplexvirus Species 0.000 description 9
- 239000000725 suspension Substances 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 6
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 229940037003 alum Drugs 0.000 description 6
- 208000009889 Herpes Simplex Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 229940040731 human interleukin-12 Drugs 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7450398P | 1998-02-12 | 1998-02-12 | |
| US60/074,503 | 1998-02-12 | ||
| PCT/US1999/002923 WO1999040938A2 (en) | 1998-02-12 | 1999-02-10 | Vaccines comprising interleukin-12 and herpes simplex viral antigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002502884A JP2002502884A (ja) | 2002-01-29 |
| JP2002502884A5 true JP2002502884A5 (https=) | 2006-03-02 |
Family
ID=22119907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000531189A Pending JP2002502884A (ja) | 1998-02-12 | 1999-02-10 | インターロイキン−１２および単純ヘルペスウイルス抗原を含んでなるワクチン |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6488936B1 (https=) |
| EP (1) | EP1053017B1 (https=) |
| JP (1) | JP2002502884A (https=) |
| KR (1) | KR100622716B1 (https=) |
| CN (1) | CN1224422C (https=) |
| AT (1) | ATE275421T1 (https=) |
| AU (1) | AU764036B2 (https=) |
| BR (1) | BR9907883A (https=) |
| CA (1) | CA2320041A1 (https=) |
| DE (1) | DE69919984T2 (https=) |
| DK (1) | DK1053017T3 (https=) |
| ES (1) | ES2226338T3 (https=) |
| IL (1) | IL137811A (https=) |
| PT (1) | PT1053017E (https=) |
| WO (1) | WO1999040938A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ515322A (en) * | 1999-05-13 | 2004-03-26 | Wyeth Corp | Adjuvant combination formulations |
| ES2258987T3 (es) * | 1999-12-17 | 2006-09-16 | Wyeth Holdings Corporation | Vacuna para reforzar las respuestas inmunitarias al virus del herpes simple. |
| US20070025958A1 (en) | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
| AU2002232560A1 (en) | 2000-10-27 | 2002-05-06 | Immuno-Rx, Inc | Vaccine immunotherapy for immune suppressed patients |
| IL155690A0 (en) * | 2000-11-10 | 2003-11-23 | Wyeth Corp | Adjuvant combination formulations |
| US6867000B2 (en) | 2000-12-07 | 2005-03-15 | Wyeth Holdings Corporation | Method of enhancing immune responses to herpes |
| JP2004099584A (ja) * | 2002-05-02 | 2004-04-02 | Keio Gijuku | Ｈｓｖを用いた抗腫瘍剤 |
| CN1301749C (zh) * | 2005-12-09 | 2007-02-28 | 复旦大学 | 抗单纯疱疹病毒－2感染的多表位dna疫苗及其制备方法 |
| US7790203B2 (en) * | 2005-12-13 | 2010-09-07 | Lowder Tom R | Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions |
| PL2068918T5 (pl) | 2006-09-26 | 2024-12-02 | Access To Advanced Health Institute | Kompozycja szczepionki zawierająca syntetyczny adiuwant |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| CA3017298C (en) | 2009-05-15 | 2021-09-28 | Irx Therapeutics, Inc. | Compositions comprising primary cell-derived biologics for enhancing immune responses in patients |
| CA2764374C (en) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
| US8729058B2 (en) | 2009-10-27 | 2014-05-20 | Michael Zasloff | Methods and compositions for treating and preventing viral infections |
| ES2667476T3 (es) | 2009-12-08 | 2018-05-11 | Irx Therapeutics, Inc. | Método para invertir la supresión inmunitaria de células de Langerhans |
| EA027236B1 (ru) | 2011-04-08 | 2017-07-31 | Иммьюн Дизайн Корп. | Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа |
| HRP20181102T1 (hr) | 2012-05-16 | 2018-09-07 | Immune Design Corp | Cjepiva za hsv-2 |
| MX370573B (es) | 2013-04-18 | 2019-12-17 | Immune Design Corp | Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer. |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| WO2017196943A1 (en) | 2016-05-10 | 2017-11-16 | Minneapolis Medical Research Foundation | Cytokine signaling immunomodulators and methods |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994022473A1 (en) * | 1993-04-01 | 1994-10-13 | University Of Washington | Use of interleukin 7 to improve vaccine potency |
| US5571515A (en) * | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
| IL114576A0 (en) * | 1994-07-22 | 1995-11-27 | Merck & Co Inc | Polynucleotide herpes virus vaccine |
| GB9422990D0 (en) * | 1994-11-15 | 1995-01-04 | Cortecs Ltd | Immunogenic compositions |
| WO1998008947A1 (en) * | 1995-12-19 | 1998-03-05 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Enhancement of dna immunization through the use of cytokines |
-
1999
- 1999-02-10 JP JP2000531189A patent/JP2002502884A/ja active Pending
- 1999-02-10 AT AT99905946T patent/ATE275421T1/de not_active IP Right Cessation
- 1999-02-10 WO PCT/US1999/002923 patent/WO1999040938A2/en not_active Ceased
- 1999-02-10 CN CNB998043311A patent/CN1224422C/zh not_active Expired - Fee Related
- 1999-02-10 BR BR9907883A patent/BR9907883A/pt not_active Application Discontinuation
- 1999-02-10 US US09/247,635 patent/US6488936B1/en not_active Expired - Fee Related
- 1999-02-10 EP EP19990905946 patent/EP1053017B1/en not_active Expired - Lifetime
- 1999-02-10 DE DE1999619984 patent/DE69919984T2/de not_active Expired - Fee Related
- 1999-02-10 IL IL13781199A patent/IL137811A/en not_active IP Right Cessation
- 1999-02-10 CA CA 2320041 patent/CA2320041A1/en not_active Abandoned
- 1999-02-10 KR KR1020007008769A patent/KR100622716B1/ko not_active Expired - Fee Related
- 1999-02-10 DK DK99905946T patent/DK1053017T3/da active
- 1999-02-10 AU AU25981/99A patent/AU764036B2/en not_active Ceased
- 1999-02-10 ES ES99905946T patent/ES2226338T3/es not_active Expired - Lifetime
- 1999-02-10 PT PT99905946T patent/PT1053017E/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002502884A5 (https=) | ||
| JP2001523729A5 (https=) | ||
| JP2005270111A (ja) | パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法 | |
| CA2136429A1 (en) | Combined vaccines comprising hepatitis b surface antigen and other antigens | |
| HUP0004327A3 (en) | Fusion proteins containing human papilloma virus (hpv) proteins and immunological fusion partner with t-helper epitopes to the hpv antigen, as well as vaccine formulations for treatment and/or profilaxis of hpv induced lesions | |
| EP2368575A3 (en) | Dry formulation for transcutaneous immunization | |
| JP2003508495A5 (https=) | ||
| JP2001514208A5 (https=) | ||
| JP2001515870A5 (https=) | ||
| AUPP807399A0 (en) | Improved immunogenic lhrh composition and methods relating thereto | |
| JP2002502882A5 (https=) | ||
| HUP0004360A3 (en) | Papilloma virus capsomere vaccine formulations and methods of use | |
| EP1538209A3 (en) | Self-assembling recombinant hpv16 papillomavirus capsid proteins | |
| AU2001295673A1 (en) | Vaccine composition | |
| MXPA02002484A (es) | Composiciones de vacuna combinada. | |
| NZ323973A (en) | Vaccine compositions for intranasal administration comprising chitosan and use thereof | |
| NZ510198A (en) | Calcium phosphate delivery vehicle and adjuvant formulated as an injectable paste to enhance adjuvant activity | |
| WO2002000249A3 (en) | Multivalent vaccine composition | |
| JP2002542204A5 (https=) | ||
| WO2000062801A3 (en) | Combination vaccine against streptococcus pneumoniae and respiratory syncytial virus (rsv) | |
| WO1999040938A3 (en) | Vaccines comprising interleukin-12 and herpes simplex viral antigen | |
| AU2002221519A1 (en) | Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens | |
| CA2229955A1 (en) | Papilloma virus capsomere vaccine formulations and methods of use | |
| CA2352563A1 (en) | Method to produce inactivated w/o emulsion adjuvanted vaccines | |
| EP0888777A3 (en) | Recombinant bovine herpesvirus type 1 polyptpetides and vaccines |